Sanofi, the leading French pharmaceutical company, surprised the market with the abrupt dismissal of its CEO, Paul Hudson, who will leave his position on February 17, 2026. The company's board of directors convened on February 11 and decided not to renew Hudson's mandate, expressing gratitude for his significant contributions during his six-year tenure. His departure has raised questions about the company's future direction and the potential implications for its ongoing projects and strategies.

Belén Garijo, the CEO of the German laboratory Merck, has been appointed as Hudson's successor, set to take over by the end of April. This leadership change reflects possible shifts in Sanofi's operational strategies and corporate governance. Industry observers speculate that Garijo's appointment may signal a new approach, especially in areas where Sanofi seeks to innovate and expand its product offerings. The timing of this transition also suggests that the board may be looking for fresh perspectives to navigate the evolving pharmaceutical landscape.

This development is notable not only for Sanofi but also for the wider pharmaceutical industry, which is currently facing challenges such as pricing pressures, regulatory scrutiny, and the need for rapid innovation. Hudson's exit might be indicative of broader issues within Sanofi that require immediate action. Stakeholders will be watching closely to see how Garijo's leadership will impact the company as it positions itself for future growth and competition.